-
|
GlobeNewswire –
4:05 PM ET 08/09/2022
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus and other viral diseases, today announced financial results and recent highlights for the second quarter ended June 30, 2022.
|
-
|
Benzinga –
10:14 AM ET 07/21/2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Vertex Pharmaceuticals Incorporated and Verve Therapeutics Inc announced an exclusive, four-year global research collaboration to discover and develop an in vivo gene editing program for undisclosed liver disease.
|
-
|
Benzinga –
6:26 AM ET 07/21/2022
Disappointing Data Forces Assembly Bio Stop Combo Trial For HBV Infection
|
-
|
Reuters –
5:05 PM ET 07/20/2022
Assembly Biosciences Inc (ASMB): * Assembly Biosciences Inc (ASMB) - PLAN INCLUDES A REDUCTION OF WORKFORCE BY 30 EMPLOYEES, RESULTING IN A TOTAL OF ABOUT 70 REMAINING EMPLOYEES. * ASSEMBLY BIOSCIENCES (ASMB) -IMPACTED EMPLOYEES TO BE OFFERED SEPARATION BENEFITS LIKE SEVERANCE PAYMENTS, ACCELERATED VESTING OF SOME RESTRICTED STOCK UNITS.
|
-
|
Reuters –
4:59 PM ET 07/20/2022
Assembly Biosciences Inc (ASMB): * ASSEMBLY BIOSCIENCES ANNOUNCES PROGRAM REPRIORITIZATION AND ORGANIZATIONAL UPDATE. * Assembly Biosciences Inc (ASMB) - WILL RESTRUCTURE ORGANIZATION AND REDUCE ITS WORKFORCE. * Assembly Biosciences Inc (ASMB) - WILL DISCONTINUE CLINICAL DEVELOPMENT OF ITS FIRST-GENERATION INVESTIGATIONAL CORE INHIBITOR, VBR.
|
-
|
GlobeNewswire –
4:05 PM ET 07/20/2022
- Discontinues clinical development of vebicorvir, Assembly Bio’s first-generation core inhibitor, based on interim efficacy data from ongoing combination clinical studies - Advancing next-generation, significantly more potent core inhibitors, ABI-H3733 and ABI-4334, in clinical studies - Prioritizes research activities including small molecule HBV/HDV entry inhibitor, small molecule interfer...
|
-
|
Benzinga –
10:03 AM ET 06/22/2022
U.S. stocks traded lower this morning, with the Dow Jones dropping around 300 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.98% to 30,231.20 while the NASDAQ fell 0.61% to 11,001.92. The S&P also fell, dropping, 0.82% to 3,733.90.
|
-
|
Reuters –
9:22 AM ET 06/22/2022
Assembly Biosciences Inc (ASMB): * ASSEMBLY BIOSCIENCES PRESENTS NEW DATA HIGHLIGHTING CLINICAL PROGRESS OF CORE INHIBITOR PROGRAMS AT EASL'S INTERNATIONAL LIVER CONGRESS 2022 Source text for Eikon: Further company coverage:
|
-
|
GlobeNewswire –
8:00 AM ET 06/22/2022
Assembly Biosciences (ASMB), Inc. , a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus and other viral diseases, today announced data from the companys investigational core inhibitor programs ABI-H3733, ABI-4334 and vebicorvir, featured in six poster presentations at the International Liver Congress, the Annual Meeting of the Europe...
|
-
|
GlobeNewswire –
8:00 AM ET 06/21/2022
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus and other viral diseases, plans to host a webcast on Tuesday, July 26, 2022 from 1:30-2:30 pm PT/4:30-5:30 pm ET to introduce its new research program advancing a novel, small molecule interferon-α receptor agonist designed to selectively activate t...
|
-
|
GlobeNewswire –
8:00 AM ET 06/08/2022
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus and other viral diseases, today announced that six abstracts have been accepted for presentation at the International Liver Congress, the Annual Meeting of the European Association for the Study of the Liver taking place virtually and in London on J...
|
-
|
Benzinga –
11:24 AM ET 06/06/2022
Assembly Biosciences, Inc. today announced Initiation of Phase 1b clinical study of its drug candidate ABI-H3733 for Chronic Hepatitis B Virus Infection. The Phase 1b clinical trial will evaluate the safety, pharmacokinetics and antiviral activity of 3733 in adults with chronic HBV infection.
|
-
|
Reuters –
8:39 AM ET 06/06/2022
Assembly Biosciences Inc (ASMB): * ASSEMBLY BIOSCIENCES INITIATES PHASE 1B CLINICAL TRIAL EVALUATING NEXT GENERATION CORE INHIBITOR ABI-H3733 FOR THE TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION Source text for Eikon: Further company coverage:
|
-
|
GlobeNewswire –
8:00 AM ET 06/06/2022
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus and other viral diseases, today announced the initiation of a Phase 1b trial of its investigational next-generation, highly potent core inhibitor ABI-H3733.
|
-
|
GlobeNewswire –
4:05 PM ET 06/03/2022
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus and other viral diseases, today announced a grant of stock options to one new employee to purchase 16,000 shares of Assembly Bio common stock with an exercise price of $1.87 per share, the closing price of Assembly Bios common stock on June 1, 2022.
|
-
|
Benzinga –
8:46 AM ET 05/25/2022
Here's a roundup of top developments in the biotech space over the last 24 hours. The FDA has issued a Complete Response Letter regarding Verrica Pharmaceuticals Inc's marketing application for VP-102 for molluscum contagiosum.
|
-
|
Reuters –
6:37 PM ET 05/24/2022
Assembly Biosciences Inc (ASMB): * ASSEMBLY BIOSCIENCES (ASMB) - EFFECTIVE MAY 20, BECAUSE OF CLINICAL HOLD ON ATI-2173, CO TERMINATED CLINICAL TRIAL COLLABORATION AGREEMENT WITH ANTIOS Further company coverage:
|
-
|
GlobeNewswire –
4:05 PM ET 05/12/2022
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus and other viral diseases, today reported financial results and recent highlights for the first quarter ended March 31, 2022.
|
-
|
Benzinga –
12:28 PM ET 05/11/2022
On Wednesday, 807 companies reached new 52-week lows. The following stocks created new 52-week lows on Wednesday: Be sure to stay with Benzinga for further updates and market-moving news.
|
-
|
GlobeNewswire –
5:00 PM ET 04/01/2022
Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and other viral diseases, today announced a grant of stock options to one new employee to purchase 19,000 shares of the Companys common stock with an exercise price of $2.06 per share, the closing price of Assembly Bios common stock on April 1, 2022.
|
Page:
|
Today's and Upcoming Events
-
ASMB to announce Q3 earnings (Unconfirmed)
Past Events (last 90 days)
-
ASMB announced Q2 earnings.
Data provided by Thomson Reuters © 2022
|